CY1114706T1 - Μεθανοσουλφονικο αλας του 5-(2-{[6-(2,2-διφθορο-2-φαινυλαιθοξυ)εξυλ]αμινο}-1-υδροξυαιθυλ)-8-υδροξυκουινολιν-2(1η)-ενα ως αγωνιστης του βητα 2 αδρενεργικου υποδοχεα - Google Patents

Μεθανοσουλφονικο αλας του 5-(2-{[6-(2,2-διφθορο-2-φαινυλαιθοξυ)εξυλ]αμινο}-1-υδροξυαιθυλ)-8-υδροξυκουινολιν-2(1η)-ενα ως αγωνιστης του βητα 2 αδρενεργικου υποδοχεα

Info

Publication number
CY1114706T1
CY1114706T1 CY20131100050T CY131100050T CY1114706T1 CY 1114706 T1 CY1114706 T1 CY 1114706T1 CY 20131100050 T CY20131100050 T CY 20131100050T CY 131100050 T CY131100050 T CY 131100050T CY 1114706 T1 CY1114706 T1 CY 1114706T1
Authority
CY
Cyprus
Prior art keywords
phenylethoxy
difluoro
hydroxyethyl
amino
methanesulfonate
Prior art date
Application number
CY20131100050T
Other languages
English (en)
Original Assignee
Almirall, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall, S.A. filed Critical Almirall, S.A.
Publication of CY1114706T1 publication Critical patent/CY1114706T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/32—Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)

Abstract

Η παρούσα εφεύρεση εστιάζεται σε ένα μεθανοσουλφονικό άλας του 5-(2-{[6-(2,2-διφθορο-2-φαινυλαιθοξυ)εξυλ]αμινο}-1-υδροξυαιθυλ)-8-υδροξυκουινολιν-2(1Η)-ένα και στα φαρμακευτικά αποδεκτά επιδιαλυτώματα αυτού.
CY20131100050T 2008-12-22 2013-01-17 Μεθανοσουλφονικο αλας του 5-(2-{[6-(2,2-διφθορο-2-φαινυλαιθοξυ)εξυλ]αμινο}-1-υδροξυαιθυλ)-8-υδροξυκουινολιν-2(1η)-ενα ως αγωνιστης του βητα 2 αδρενεργικου υποδοχεα CY1114706T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08382082 2008-12-22
EP09793472A EP2367796B1 (en) 2008-12-22 2009-12-15 Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino }-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one as agonist of the beta 2 adrenergic receptor

Publications (1)

Publication Number Publication Date
CY1114706T1 true CY1114706T1 (el) 2016-10-05

Family

ID=40383583

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100050T CY1114706T1 (el) 2008-12-22 2013-01-17 Μεθανοσουλφονικο αλας του 5-(2-{[6-(2,2-διφθορο-2-φαινυλαιθοξυ)εξυλ]αμινο}-1-υδροξυαιθυλ)-8-υδροξυκουινολιν-2(1η)-ενα ως αγωνιστης του βητα 2 αδρενεργικου υποδοχεα

Country Status (33)

Country Link
US (1) US8563731B2 (el)
EP (1) EP2367796B1 (el)
JP (1) JP5645844B2 (el)
KR (1) KR101738700B1 (el)
CN (1) CN102264703B (el)
AR (1) AR074792A1 (el)
AU (1) AU2009331961B2 (el)
BR (1) BRPI0918370B8 (el)
CA (1) CA2748105C (el)
CL (1) CL2011001544A1 (el)
CO (1) CO6390056A2 (el)
CY (1) CY1114706T1 (el)
DK (1) DK2367796T3 (el)
EA (1) EA019440B1 (el)
ES (1) ES2397209T3 (el)
HK (1) HK1156318A1 (el)
HR (1) HRP20120941T1 (el)
IL (1) IL213161A (el)
ME (1) ME01497B (el)
MX (1) MX2011006491A (el)
MY (1) MY155609A (el)
NZ (1) NZ592797A (el)
PE (1) PE20110929A1 (el)
PL (1) PL2367796T3 (el)
PT (1) PT2367796E (el)
SG (1) SG171992A1 (el)
SI (1) SI2367796T1 (el)
SM (1) SMT201300001B (el)
TW (1) TWI412520B (el)
UA (1) UA105913C2 (el)
UY (1) UY32297A (el)
WO (1) WO2010072354A1 (el)
ZA (1) ZA201103312B (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2221055A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
DK2400950T3 (da) 2009-02-26 2019-07-29 Glaxo Group Ltd Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
EP2668941A1 (en) 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
CN103864670B (zh) * 2014-03-17 2015-08-26 苏州明锐医药科技有限公司 阿普司特的制备方法
CN105168136B (zh) * 2015-11-08 2018-03-20 长沙佰顺生物科技有限公司 一种阿普斯特传递体及其制备方法
CN105548393A (zh) * 2015-12-14 2016-05-04 成都百裕制药股份有限公司 一种检测阿普斯特原料中杂质含量的方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT334335B (de) 1973-03-01 1976-01-10 Basf Ag Verfahren zur herstellung von 1-phenyl-2-aminoathanolen-(1)
US2579479A (en) 1950-01-23 1951-12-25 Syntex Sa delta 1, 4-pregnadiene-17alpha-ol-3-ones
US2837464A (en) 1955-01-11 1958-06-03 Schering Corp Process for production of dienes by corynebacteria
US2897216A (en) 1954-11-01 1959-07-28 Schering Corp Process for the preparation of steroidal dienes and intermediates obtained thereby
US3053865A (en) 1958-03-19 1962-09-11 Merck & Co Inc Novel 16-alkyl and 16-alkylene steroids and processes
GB869511A (en) 1958-05-26 1961-05-31 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
US3007923A (en) 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
US3104246A (en) 1961-08-18 1963-09-17 Roussel Uclaf Process of preparation of beta-methasone
US3134719A (en) 1962-04-05 1964-05-26 American Cyanamid Co Calcium phosphates in tablet compressing
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
GB1247370A (en) 1968-12-31 1971-09-22 Allen & Hanburys Ltd Glyoxals and production thereof
US3678137A (en) 1970-10-15 1972-07-18 Smith Kline French Lab Adamantyl-substituted-alkyl 2-aminoethyl phosphates and phosphonates
BE786713A (fr) 1971-07-27 1973-01-25 Sandoz Sa Nouveaux amino-alcools, leur preparation et leur application comme medicaments
SE378109B (el) 1972-05-19 1975-08-18 Bofors Ab
US3975391A (en) 1973-12-26 1976-08-17 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
US4068076A (en) 1972-12-29 1978-01-10 Otsuka Pharmaceutical Co., Ltd. 5-(1-Hydroxy-2-(heterocyclic amino))ethyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
DE2310140A1 (de) 1973-03-01 1974-09-12 Basf Ag Neue 1-phenyl-2-amino-aethanolderivate und ein verfahren zu ihrer herstellung
GB1468156A (en) 1973-07-19 1977-03-23 Ici Ltd Phenylethylamine derivatives
US4022784A (en) 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-substituted-carbostyril and -3,4-dihydrocarbostyril derivatives
JPS5649907B2 (el) 1974-02-01 1981-11-25
US4026897A (en) 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
US3994901A (en) 1974-06-13 1976-11-30 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
US4145542A (en) 1974-06-13 1979-03-20 Otsuka Pharmaceutical Co., Ltd. 5- 1-Hydroxy-2-(heterocyclic-amino)!alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
DE2965655D1 (en) 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
IT7920688V0 (it) 1979-02-05 1979-02-05 Chiesi Paolo Parma Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
NZ212367A (en) 1984-06-11 1989-04-26 Glaxo Group Ltd Ethanolamine derivatives and pharmaceutical compositions
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
JPS6485964A (en) 1987-03-12 1989-03-30 Glaxo Group Ltd Compound
DK633588A (da) 1987-11-13 1989-05-14 Glaxo Group Ltd Aminderivater
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
EP0416925A3 (en) 1989-09-07 1991-09-25 Glaxo Group Limited Use of 4-hydroxy-alpha 1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol or its salts in the treatment of allergy and inflammation
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
US5507281A (en) 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
DK0503031T3 (da) 1990-09-26 1999-01-04 Pharmachemie Bv Inhalator med et reservoir til flere doser af et materiale, der skal inhaleres
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
IL107120A (en) 1992-09-29 1997-09-30 Boehringer Ingelheim Int Atomising nozzle and filter and spray generating device
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
CZ287848B6 (en) 1992-12-18 2001-02-14 Schering Corp Inhalator of powder substances
FR2708604B1 (fr) * 1993-07-30 1995-10-20 Sanofi Elf Utilisation de dérivés de benzènesulfonyl-indole pour la préparation de médicaments.
DE69617431T2 (de) 1995-06-21 2002-08-01 Asta Medica Ag Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
ATE215369T1 (de) 1996-09-05 2002-04-15 Lilly Co Eli Carbazolanaloge als selektive beta3-adrenergische agonisten
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
IL154175A0 (en) 2000-08-05 2003-07-31 Glaxo Group Ltd 17. beta.-carbothioate 17. alpha-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
EP1577291A1 (en) 2004-03-17 2005-09-21 Pfizer Limited Phenylethanolamine derivatives as beta-2 agonists
EP1730103B1 (en) 2004-03-23 2010-05-26 Pfizer Limited Formamide derivatives useful as adrenoceptor
CN1984876A (zh) 2004-06-03 2007-06-20 施万制药 二胺类β2肾上腺素能受体激动剂
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2006014704A1 (en) 2004-07-21 2006-02-09 Theravance, Inc. DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US20060205949A1 (en) 2005-03-10 2006-09-14 Theravance, Inc. Crystalline forms of a biphenyl compound
ES2265276B1 (es) * 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2296516B1 (es) 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
MX2008015901A (es) * 2006-06-12 2009-01-12 Novartis Ag Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]met il]fenil]-2e-2-propenamida.
FR2903168B1 (fr) * 2006-06-30 2008-08-22 Fayard Eliane Bruleur pour realiser la combustion de substances reputees difficilement combustibles
ES2302447B1 (es) 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320961B1 (es) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2221055A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
EP2221297A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one

Also Published As

Publication number Publication date
EA201100970A1 (ru) 2011-12-30
SMT201300001B (it) 2013-03-08
KR20110103397A (ko) 2011-09-20
HK1156318A1 (en) 2012-06-08
JP5645844B2 (ja) 2014-12-24
CO6390056A2 (es) 2012-02-29
SI2367796T1 (sl) 2012-12-31
PL2367796T3 (pl) 2013-02-28
MY155609A (en) 2015-11-13
IL213161A (en) 2014-09-30
PE20110929A1 (es) 2011-12-29
WO2010072354A1 (en) 2010-07-01
EP2367796B1 (en) 2012-10-24
HRP20120941T1 (hr) 2012-12-31
CL2011001544A1 (es) 2011-11-11
ME01497B (me) 2014-04-20
NZ592797A (en) 2012-08-31
TWI412520B (zh) 2013-10-21
CA2748105A1 (en) 2010-07-01
AU2009331961B2 (en) 2015-11-12
BRPI0918370B1 (pt) 2020-10-13
CA2748105C (en) 2017-05-30
MX2011006491A (es) 2011-07-13
EA019440B1 (ru) 2014-03-31
DK2367796T3 (da) 2012-12-17
CN102264703A (zh) 2011-11-30
JP2012513424A (ja) 2012-06-14
IL213161A0 (en) 2011-07-31
PT2367796E (pt) 2013-01-23
EP2367796A1 (en) 2011-09-28
BRPI0918370B8 (pt) 2021-05-25
ZA201103312B (en) 2012-01-25
AU2009331961A1 (en) 2011-06-30
UY32297A (es) 2010-05-31
KR101738700B1 (ko) 2017-05-22
ES2397209T3 (es) 2013-03-05
US20110251234A1 (en) 2011-10-13
SG171992A1 (en) 2011-07-28
UA105913C2 (uk) 2014-07-10
TW201024265A (en) 2010-07-01
US8563731B2 (en) 2013-10-22
CN102264703B (zh) 2014-07-30
AR074792A1 (es) 2011-02-09

Similar Documents

Publication Publication Date Title
CY1114706T1 (el) Μεθανοσουλφονικο αλας του 5-(2-{[6-(2,2-διφθορο-2-φαινυλαιθοξυ)εξυλ]αμινο}-1-υδροξυαιθυλ)-8-υδροξυκουινολιν-2(1η)-ενα ως αγωνιστης του βητα 2 αδρενεργικου υποδοχεα
CY1113366T1 (el) Αλας ναραdisylate του 5-(2-{[6-(2,2-difluoro-2-ρηενυlετηοχυ)ηεχυl]αμινο}-1-ηυdroχυετηυl)-8-ηυdrοχυquinolin-2(1η)-ονε σαν αγωνιστικο του αδρενεργικου ληπτη βητα 2
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
HK1147748A1 (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors alk c-met 24-
EA200701853A1 (ru) Производные циклопентапиридина и тетрагидрохинолина
IL209124A0 (en) Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
ATE502027T1 (de) Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren
DK2398473T3 (da) 5-(2-{[6-(2, 2-difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2-(1H)-on til behandling af lungefunktion
EA201101299A1 (ru) Способ получения 5-(2-{[6-(2,2-дифтор-2-фенилэтокси)гексил]амино}-1-гидроксиэтил)-8-гидроксихинолин-2(1h)-oha
EA200970894A1 (ru) Производные хинолина в качестве лигандов рецепторов crth2
IL213980A0 (en) 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-l-hydroxyethyl)-8-hydroxyquinolin-2 (1h)-one and its use in the treatment of pulmonary diseases
EA201170585A1 (ru) Производные изохинолинона в качестве антагонистов nk3
EA201400425A1 (ru) Способ получения 5-(2-{[6-(2,2-дифтор-2-фенилэтокси)гексил]амино}-1(r)-гидроксиэтил)-8-гидроксихинолин-2(1h)-она через новый промежуточный продукт
ATE540929T1 (de) Isochinolinonderivate als nk3-antagonisten
NO20071324L (no) Kombinasjon av substituerte benzimidazoler og triazinderivater med antiparasittisk virkning
RS52636B (en) MESILATE IS 5- (2 - {[6- (2,2-DIFLUORO-2-PHENYLETOXY) HEXYL] AMINO} -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONE AS AN ANTAGONIST OF BETA 2 ADRENERGY RECEPTOR
IL192593A0 (en) Combination of triazine derivatives and ppar?? agonists